quinazolines has been researched along with pyrroles in 360 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (1.39) | 18.7374 |
| 1990's | 5 (1.39) | 18.2507 |
| 2000's | 106 (29.44) | 29.6817 |
| 2010's | 231 (64.17) | 24.3611 |
| 2020's | 13 (3.61) | 2.80 |
| Authors | Studies |
|---|---|
| De Martino, G; Massa, S | 1 |
| Schäfer, J; Stein, M | 1 |
| Johne, S | 1 |
| Crippen, GM; Ghose, AK | 1 |
| Sakamoto, S; Samejima, K | 1 |
| Taylor, EC | 1 |
| Eberhard, ML; Ellis, WL; Marley, SE; McGreevy, PB; Ruebush, TK; Steurer, FJ | 1 |
| Deangelis, DV; Studenberg, SD; Wargin, WA; Woolley, JL | 1 |
| Ahn, HS; Arik, L; Boykow, G; Burnett, DA; Caplen, MA; Czarniecki, M; Domalski, MS; Foster, C; Manna, M; Stamford, AW; Wu, Y | 1 |
| Elbaum, D; Lydon, NB; Toledo, LM | 1 |
| Casadei, B; Musialek, P; Paterson, DJ; Rigg, L; Terrar, DA | 1 |
| Ahn, HS; Boykow, G; Foster, C; Graziano, M; Manna, M; Stamford, A | 1 |
| Class, R; Foster, C; Lord, ST; Marchese, P; Morgan, DA; Ruggeri, ZM; Soslau, G | 1 |
| Kuwano, M; Ono, M | 1 |
| Fry, DW; Slichenmyer, WJ | 1 |
| Alcaraz, MJ; Gonzalez-Tejero, A; Molina, P; Rioja, I; Tárraga, A; Terencio, MC; Ubeda, A | 1 |
| Baselga, J; Hammond, LA | 1 |
| Garber, K | 2 |
| Rosen, LS | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Bonomi, P | 1 |
| Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A | 1 |
| Davidson, AJ; Goishi, K; Klagsbrun, M; Lee, P; Nishi, E; Zon, LI | 1 |
| Shiotsu, Y | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
| Kobayashi, K | 1 |
| Argade, NP; Mhaske, SB | 1 |
| Bhide, R; Borzilleri, R; Fargnoli, J; Fink, B; Gullo-Brown, J; Han, WC; Hunt, JT; Mitt, T; Mortillo, S; Vite, G; Wautlet, B; Wong, T; Yu, C; Zheng, X | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Rabindran, SK | 1 |
| Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Ganti, AK; Potti, A | 1 |
| Thompson, JE | 1 |
| Ager, A; Gerena, L; Guan, J; Lin, AJ; O'Neil, M; Obaldia, N; Zhang, Q | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Kiyoi, H | 1 |
| Bergman, RG; Ellman, JA; Wiedemann, SH | 1 |
| Cussac, D; De Vries, L; Finana, F; Le Grand, B; Palmier, C; Perez, M | 1 |
| Bergmann, S; Henklein, P; Hollenberg, MD; Junker, K; Kaufmann, R; Settmacher, U | 1 |
| Flordellis, CS; Kritikou, S; Maragoudakis, ME; Tsopanoglou, NE; Zania, P | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Li, Q; Lin, AJ; Skillman, DS; Smith, K; Xie, LH; Zhang, J | 1 |
| Borner, MM | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Gasparini, G; Longo, R; Sarmiento, R | 1 |
| Hampton, T | 1 |
| Teng, CM; Wu, CC | 1 |
| Halangk, W; Luo, W; Reiser, G; Sahin-Tóth, M; Wang, Y; Wartmann, T | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Bankhead, C | 1 |
| Curtiss, FR | 1 |
| Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Taguchi, T; Yang, Y; Zhu, WG | 1 |
| Bowman, WR; Elsegood, MR; Stein, T; Weaver, GW | 1 |
| Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM | 1 |
| Herbst, RS | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Baker, JE; Fu, X; Gross, GJ; Hsu, A; Strande, JL; Su, J | 1 |
| Anova, L; Kozar, MP; Li, Q; Lin, AJ; Milhous, WK; Shearer, TW; Si, Y; Skillman, DR; Smith, KS; Xie, LH; Zhang, J | 1 |
| Cirino, G; Di Serio, C; Duarte, M; Geppetti, P; Marchionni, N; Masotti, G; Massi, D; Naldini, A; Pellerito, S; Prudovsky, I; Santucci, M; Tarantini, F | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Ablonczy, Z; Crosson, CE | 1 |
| Zhu, AX | 1 |
| Di Serio, C; Pellerito, S; Tarantini, F | 1 |
| Changelian, PS; Doty, JL; Flanagan, ME; Harris, TM; Kent, CR; Kudlacz, EM; Kuhn, CF; Magnuson, KS; Moshinsky, D; Munchhof, MJ; Perregaux, DG; Sawyer, PS; Sun, J; Whipple, DA | 1 |
| Chapman, J; Maggio, N; Segal, M; Shavit, E | 1 |
| Ehninger, G; Illmer, T | 1 |
| Giordano, S; Petrelli, A | 1 |
| Kulkarni, SS; Patel, MR; Talele, TT | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Jahng, KC; Jahng, Y; Kim, DH; Kim, SI; Lee, ES; Lee, SH; Seo, CS; Son, JK | 1 |
| Hashizume, H; Kamio, N; Matsushima, K; Nakao, S; Sugiya, H | 1 |
| Gluck, N; Krimsky, M; Schwob, O; Yedgar, S | 1 |
| Lee, CB; Socinski, MA | 1 |
| Buhl, R; Fischer, B | 1 |
| Choi, JW; Choi, MS; Go, HS; Jeon, SJ; Kim, SD; Kim, WK; Kim, YE; Ko, KH; Lee, WJ; Park, GH; Shin, CY; Shin, SM | 1 |
| Gettinger, S | 1 |
| Chen, HM; Chou, DS; Fong, TH; Hsiao, G; Hsu, CY; Lin, CH; Shen, MY; Sheu, JR | 1 |
| Nahleh, ZA | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Bengtsson, T; Grenegård, M; Lindahl, TL; Nylander, M | 1 |
| Dolman, ME; Fretz, MM; Goldschmeding, R; Hennink, WE; Kok, RJ; Lacombe, M; Nguyen, TQ; Pato, J; Prakash, J; Storm, G | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Motley, ED; Watts, VL | 1 |
| Iyengar, L; Lovicu, FJ; McAvoy, JW; Patkunanathan, B | 1 |
| Dong, Z; Fu, L; Gao, X; Ji, C; Li, L; Liu, H; Luo, X; Mei, C; Xiong, X; Zhang, Y | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Horn, L; Sandler, AB | 1 |
| Guo, Z; Zhao, H | 1 |
| Baumert, C; Hilgeroth, A | 1 |
| Bocquet, A; Calmettes, Y; Culié, C; Le Grand, B; Leparq-Panissié, A; Létienne, R | 1 |
| Baier, G; Brinkmann, V; Cottens, S; Evenou, JP; Gruber, T; Guntermann, C; Hermann-Kleiter, N; Kaminski, S; Kovarik, J; Letschka, T; Lutz-Nicoladoni, C; Thuille, N; Towbin, H; Wagner, J; Wagner, K; Weitz-Schmidt, G; Welzenbach, KA; Zenke, G | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK | 1 |
| Angelillo-Scherrer, A; Hirt, L; Price, M; Thevenet, J | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Chen, CL; Lo, HM; Tsai, YJ; Wu, PH; Wu, WB | 1 |
| Chandler, PA; Huang, HL; Kovarik, JM; Sfikas, N; Slade, A | 1 |
| Kohsaka, S; Maeda, S; Nakajima, K; Tohyama, Y | 1 |
| Stang, JL; Tran, LM; Zhong, H | 1 |
| Dent, P; Grant, S; Martin, AP; Mitchell, C; Nephew, KP; Rahmani, M | 1 |
| Albert, R; Beerli, C; Cooke, N; Cottens, S; Cowan-Jacob, SW; Ehrhardt, C; Evenou, JP; Geiser, M; Rummel, G; Sedrani, R; Stark, W; Strauss, A; von Matt, P; Wagner, J; Weckbecker, G; Zenke, G | 1 |
| Manicassamy, S | 1 |
| Amaravadi, R | 1 |
| Sommerer, C; Zeier, M | 1 |
| Blankesteijn, WM; Smits, JF; Verkaar, F; Zaman, GJ | 1 |
| Sherman, SI | 1 |
| Beerli, C; Bruns, C; Burkhart, C; Metzler, B; Morris, RE; Pally, C; Wagner, J; Weckbecker, G; Wieczorek, G | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A | 1 |
| Budde, K; Kramer, S; Ladhoff, J; Lorkowski, C; Mashreghi, MF; Matz, M; Neumayer, HH; Weber, U | 1 |
| Asderakis, A; Barten, MJ; Becker, T; Budde, K; Dantal, J; Grinyo, JM; Ng, J; Pietruck, F; Rigotti, P; Sommerer, C; Weber, M | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Crow, KR; Gakhar, G; Hua, DH; Nguyen, TA; Perchellet, EM; Perchellet, JP; Shi, A | 1 |
| Antunes, MC; Bartlett, M; Kovarik, JM; Marbach, P; Rordorf, C; van Marle, S; Winter, S | 1 |
| Baum, MS; Chen, I; Ginsberg, MS; Harmon, CS; Hudes, GR; Kim, ST; Motzer, RJ; Redman, BG | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Ban, HS; Nakamura, H; Uno, M | 1 |
| Grenet, O; Kovarik, JM; Seiberling, M; Sfikas, N; Slade, A; Stitah, S; Straube, F; Vitaliti, A; Winter, S | 2 |
| Dalhaug, A; Nieder, C | 1 |
| Cooper, JE; Wiseman, AC | 1 |
| Fang, YH; Jeong, HJ; Joo, DJ; Kim, JY; Kim, MS; Kim, YS; Lim, BJ | 1 |
| Bocquet, A; Bourbon, T; Le Grand, B; Létienne, R; Nadal-Wollbold, F | 1 |
| Kovarik, JM; Slade, A | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Bowen, D; Byrd, J; Call, T; Erlichman, C; Ghosh, A; Hanson, C; Jelinek, D; Kay, N; Laplant, B; Laumann, K; Shanafelt, T; Villalona-Calero, M; Wu, W; Zent, C | 1 |
| Gorbacheva, LR; Makarova, AM; Mikhailova, AG; Pinelis, VG; Rumsh, LD; Savinkova, IV; Strukova, SM | 1 |
| Cillo, U; Gatlik, E; Kovarik, JM; Meiser, K; Neuhaus, P; Slade, A; Stitah, S; Weber, M | 1 |
| Budde, K; Glander, P; Mashreghi, MF; Matz, M; Naik, M; Neumayer, HH | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Arns, W; Budde, K; Dantal, J; Grinyo, JM; Kovarik, JM; Proot, P; Rostaing, L; Steiger, JU | 1 |
| Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Chu, YH; Chu, YW; Hwang, J; Lin, CM; Tsai, HP; Tseng, MC | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Chen, L; Dörken, B; Enns, A; Lenz, G; Lenz, P; Loo, A; Naylor, TL; Ratsch, BA; Schuler, W; Stegmeier, F; Tang, H; Warmuth, M; Waters, NJ; Yao, YM | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Addeo, R; Caraglia, M | 1 |
| Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Camaioni, A; Mlynarcikova, A; Nagyova, E; Nemcova, L; Prochazka, R; Salustri, A; Scsukova, S | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Abrams, K; Arns, W; Banas, B; Budde, K; Chan, L; Cibrik, D; Friman, S; Klempnauer, J; Mulgaonkar, S; Nashan, B; Nicholson, M; Vincenti, F; Wahlberg, J; Wissing, KM; Witte, S; Woodle, ES | 1 |
| Kaplan, B; Meier-Kriesche, HU | 1 |
| Geoerger, B; Leblond, P | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Chastain, EM; Getts, DR; Getts, MT; Martin, A; Miller, SD; Shankar, S; Wood, K | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bai, L; Evans, CP; Kung, HJ; Mack, PC; Ok, JH; Yang, JC | 1 |
| Albert, R; Beerli, C; Cooke, NG; Cottens, S; Evenou, JP; Faller, B; Jean, C; Sedrani, R; von Matt, P; Wagner, J; Weckbecker, G; Wiegand, H; Zenke, G | 1 |
| Fang, YH; Huh, KH; Joo, DJ; Kim, MS; Kim, YS; Lim, BJ; Suh, H | 1 |
| Cunningham, D; Yim, KL | 1 |
| Gerl, M; Höcherl, K; Schweda, F | 1 |
| Cortes, J; Roché, H | 1 |
| Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ | 1 |
| Busuttil, RW; Kamo, N; Ke, B; Kupiec-Weglinski, JW; Shen, XD | 1 |
| Becker, T; Chicano Wust, I; Ciesek, S; Heidrich, B; Helfritz, FA; Manns, MP; Pietschmann, T; Rohrmann, K; Schulze, A; Steinmann, E; Urban, S; von Hahn, T | 1 |
| Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Berkova, Z; Koblas, T; Leontovyč, I; Pektorova, L; Saudek, F; Zacharovova, K | 1 |
| Todo, S; Yamashita, K | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Audet, M; Beerli, C; Bigaud, M; Blancher, A; Heusser, C; Morris, RE; Wagner, J; Wieczorek, G | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Tang, Y | 1 |
| Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A | 1 |
| Altman, A; Kong, KF | 1 |
| Döme, B; Török, S | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Cheng, M; Feng, L; Hao, F; Ma, C; Pan, L; Tian, Y; Zhang, L | 1 |
| Du, J; Gao, G; Jin, Y; Li, H; Li, Y; Liu, H; Liu, T; Pei, G; Wei, B; Wei, L; Yue, R | 1 |
| Chudasama, J; Guttikar, S; Guy, B; Jakab, A; Kovarik, JM; Kretz, O; Picard, F; Raccuglia, M; Singhal, P; Winter, S | 1 |
| Barth, M; Fender, AC; Fischer, JW; Hohlfeld, T; Kurt, M; Mahajan, SG; Meyer-Kirchrath, J; Rauch, BH; Sagban, TA; Schrör, K | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Aldrees, A; El Eter, EA | 1 |
| Fletcher, JA; Hodi, FS; Li, J; Wu, X; Zhu, M | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Budde, K; Doueiri, S; Fabritius, K; Lehnert, M; Lorkowski, C; Mashreghi, MF; Matz, M; Neumayer, HH; Unterwalder, N; Weber, UA | 1 |
| Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S | 1 |
| Anbarasu, A; Jha, DK; Lavanya, P; Panda, L; Ramaiah, S | 1 |
| Catar, R; Chaykovska, L; Dragun, D; Fuller, TF; Haller, M; Hoff, U; Kusch, A; Pützer, J; Troppmair, J | 1 |
| Bottai, G; Santarpia, L | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, H; Tang, Y | 1 |
| Kim, CH; Ma, Q; Manaenko, A; Sun, X; Yan, J; Zhang, JH | 1 |
| Attwood, BK; Bourgognon, JM; Forsythe, ID; John Challiss, RA; Mucha, M; Patel, SG; Pawlak, R; Salah-Uddin, H; Schiavon, E; Shah, RS; Skrzypiec, AE | 1 |
| Pfister, C; Pfrommer, H; Roser, F; Tatagiba, MS | 1 |
| Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
| Hamilton, JR; Lee, H | 1 |
| Klintmalm, GB; Ruiz, R | 1 |
| Bouwens, EA; Burnier, L; Griffin, JH; Mosnier, LO; Sinha, RK | 1 |
| Chang, AY; Wang, M | 1 |
| Bergeron, P; Blackwood, E; Bowman, KK; Chen, YH; Deshmukh, G; Ding, X; Epler, J; Koehler, MF; Lau, K; Lee, L; Liu, L; Ly, C; Lyssikatos, JP; Malek, S; Nonomiya, J; Oeh, J; Ortwine, DF; Pei, Z; Sampath, D; Sideris, S; Trinh, L; Truong, T; Wu, J | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM | 1 |
| Beckebaum, S; Cicinnati, VR; Kabar, I; Radtke, A | 1 |
| Amariglio, N; Blatt, I; Chapman, J; Dominissini, D; Itsekson, Z; Maggio, N; Rechavi, G; Tanne, D | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Budde, K; Fabritius, K; Lehnert, M; Lorkowski, C; Mashreghi, MF; Matz, M; Neumayer, HH; Weber, UA | 1 |
| Caner, B; Chen, S; Fujii, M; Klebe, D; Ma, Q; Manaenko, A; Yan, J; Zhang, JH; Zhou, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Baan, CC; Kraaijeveld, R; Vafadari, R; Weimar, W | 1 |
| Harmann, LM; Meyer, J; Petersen, M; Routhu, KV; Sonin, DL; Strande, JL; Wakatsuki, T | 1 |
| Brewer, M; Janakiram, NB; Mohammed, A; Rao, CV; Steele, VE; Vedala, K | 1 |
| Budde, K; Campistol, JM; Eris, J; Gopalakrishnan, U; Hartmann, A; Kho, MM; Klupp, J; Krishnan, I; Rostaing, L; Russ, G; Tedesco-Silva, H; Vitko, S | 1 |
| Budde, K; Chodoff, L; Cohney, S; Eris, J; Gill, J; Klupp, J; Kuypers, DR; Langer, RM; Ng, J; Russ, GR; Sommerer, C; Tedesco-Silva, H; von Zur-Mühlen, B; Witzke, O; Woodle, ES | 1 |
| Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Chouhan, M; Gahtory, D; Nair, VA; Sharma, R | 1 |
| Cooley, C; Dobberfuhl, AD; Goldschmeding, R; Higgins, PJ; Meldrum, KK; Overstreet, JM; Patel, S; Samarakoon, R | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Agama, K; Barresi, E; Cosconati, S; Da Settimo, F; Di Leva, FS; Di Santo, R; La Motta, C; Marchand, C; Marinelli, L; Marini, AM; Novellino, E; Pommier, Y; Pugliesi, I; Salerno, S; Simorini, F; Taliani, S | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW | 1 |
| Baan, C; de Weerd, A; Kho, M; Kraaijeveld, R; Weimar, W; Zuiderwijk, J | 1 |
| Ding, JF; Zhong, DF | 1 |
| Bossart, W; Etter, A; Fehr, T; Hässig, A; Müller, N; Roos, M; Schiesser, M; Wüthrich, RP | 1 |
| Bastian, BC; Chen, X; Emery, C; Jager, MJ; Porter, D; Tan, L; Wu, Q | 1 |
| Bursavich, MG; Cimbora, DM; Dastrup, D; Kumar, DV; Shenderovich, M; Williams, B; Yager, KM | 1 |
| Boots, AMH; He, X; Joosten, I; Keijsers, R; Koenen, HJPM; Koerber, A; Smeets, RL; van de Kerkhof, PC; van Rijssen, E | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Chen, Z; Gao, F; Hua, Y; Keep, RF; Liu, F; Xi, G | 1 |
| Chapman, J; Itzekson, Z; Maggio, N; Milman, A; Pick, CG; Shavit, E | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Bhang, HE; Chan, FC; Cooke, VG; Derti, A; Dietze, K; Dörken, B; Farsidjani, A; Frick, M; Fritsch, C; Gascoyne, RD; Hummel, M; Kauffmann, A; Kim, S; Korn, JM; Kovats, S; Kridel, R; Lenz, G; Meissner, B; Monahan, J; Morrissey, MP; Naylor, T; Pfister, E; Rahal, R; Rakiec, D; Romero, R; Ruddy, D; Sellers, WR; Stegmeier, F; Steidl, C; Tzankov, A | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Yaqub, F | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Barraja, P; Brun, P; Carbone, A; Castagliuolo, I; Cirrincione, G; Diana, P; Issinger, OG; Montalbano, A; Parrino, B; Primac, I; Salvador, A; Spanò, V; Tisi, S; Vedaldi, D | 1 |
| Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF | 1 |
| Ambrosini, G; de Stanchina, E; Musi, E; Schwartz, GK | 1 |
| Chen, CY; Huang, SD; Lu, ZJ; Sun, YM; Tao, KM; Tao, Y; Yang, LQ; Yu, WF | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A | 1 |
| Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F | 1 |
| Andritsos, L; Awan, FT; Blachly, JS; Byrd, JC; Cannon, M; Chen, CS; El-Gamal, D; Jones, J; LaFollette, TD; Lapalombella, R; Lehman, A; Maddocks, K; Williams, E; Williams, K; Woyach, JA; Wu, CH; Zhang, X; Zhong, Y | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
| Galvis-Carvajal, E; Gomer, RH; White, MJ | 1 |
| Chan, SH; Chu, PM; Hung, CH; Tsai, KL | 1 |
| García, Á; Izquierdo, I; Rosa, I; Vélez, P | 1 |
| Barouch-Bentov, R; Berkerman, E; Einav, S; Mulholland, J; Neveu, G; Ziv-Av, A | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Bijarnia, M; De Simone, P; Isoneimi, H; Klupp, J; Krishnan, I; Pascher, A; Pirenne, J; Pratschke, J; Salamé, E | 1 |
| Levy, G; Trotter, JF | 1 |
| Hamburger, AW; Lee, Y; Mitchell, BS; Nguyen, le XT; Sunwoo, JB; Urbani, L; Utz, PJ | 1 |
| Holmes, GL; Isaev, D; Isaeva, E; Lunko, O; Lushnikova, I; Maximyuk, O; Romanov, A; Skibo, GG; Tian, C; Zapukhliak, O | 1 |
| Takahashi, M | 1 |
| Bekerman, E; Einav, S | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Han, ZQ; Huang, J; Pan, XY; Peng, L; Song, YK; Yin, GQ | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Crafter, C; Davies, BR; Dudley, P; James, NH; Klinowska, T; Tang, E; Vincent, JP | 1 |
| Berhan, A; Harris, T; Keenan, CR; Langenbach, S; Royce, SG; Schuliga, M; Stewart, AG | 1 |
| Adamus, G; Amundson, D; Boon, CJ; Haanen, JB; Jager, MJ; Kapiteijn, EH; Keunen, JE; Luyten, GP; Marinkovic, M; van Dijk, EH; van Herpen, CM | 1 |
| Acaz-Fonseca, E; Garcia-Segura, LM; Ghorbanpoor, S; Grassi, D; Ruiz-Palmero, I | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Covell, LL; Ganti, AK | 1 |
| Biddick, L; Brewer, M; Devarkonda, V; Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE | 1 |
| Mishra, N; Nugent, WH; Strauss, JF; Walsh, SW | 1 |
| Flores, J; Klebe, D; Krafft, PR; Lekic, T; Rolland, WB; Tang, J; Zhang, JH | 2 |
| Darras, FH; Decker, M; Khan, N; Nurulain, SM; Saad, A; Sadek, B | 1 |
| Cheng, XD; Feng, L; Gu, JF; Jia, XB; Yuan, JR | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Jiang, M; Liu, TT; Shen, GF; Shi, JH; Wang, Q | 1 |
| Hayama, T; Kamio, N; Matsushima, K; Muromachi, K; Okabe, T | 1 |
| Jasrai, YT; Kumar, SP; Pandya, HA | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Ott, G; Rauert-Wunderlich, H; Rosenwald, A; Rudelius, M | 1 |
| Aguiar, W; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Franco, M; Gerbase de Lima, M; Hannun, P; Medina-Pestana, J; Sandes-Freitas, T; Tedesco-Silva, H | 1 |
| Chu, LX; He, LP; Liang, ZS; Mo, CG; Qin, YQ; Wang, XD; Xie, J; Yang, F; Zhou, SX | 1 |
| Vincenti, F; Webber, AB | 1 |
| Crijns, HJ; De Boer, HC; De Jong, AM; Kamphuisen, PW; Kuiper, M; Lau, DH; Linz, D; Lumeij, S; Maass, AH; Rienstra, M; Schotten, U; Spronk, HM; Ten Cate, H; Van Gelder, IC; van Hunnik, A; van Zonneveld, AJ; Verheule, S; Zeemering, S | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Walton, JC | 1 |
| Carita, G; Cassoux, N; Dahmani, A; De Koning, L; Decaudin, D; Emery, C; Frisch-Dit-Leitz, E; Halilovic, E; Jeay, S; Laurent, C; Némati, F; Piperno-Neumann, S; Raymondie, C; Roman-Roman, S; Schoumacher, M; Wylie, A | 1 |
| Darras, FH; Decker, M; Khan, N; Pockes, S; Sadek, B | 1 |
| Abdelnabi, R; Delang, L; Leyssen, P; Near, KE; Neyts, J; Staveness, D; Wender, PA | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Al-Masri, AA; El Eter, EA; Lateef, R; Mohamed, OY | 1 |
| Bañon-Maneus, E; Campistol, JM; Diekmann, F; Hierro-Garcia, N; Martina, MN; Moya Rull, D; Ramirez Bajo, MJ; Revuelta, I; Rovira, J | 1 |
| Diao, Y; Gao, N; Jiang, W; Jin, G; Jin, Z; Li, W; Liu, Y; Wang, X; Wang, Z; Zhong, J | 1 |
| Abdelnabi, R; Amrun, SN; Delang, L; Leyssen, P; Neyts, J; Ng, LF | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Bogovyk, R; Fedoriuk, M; Holmes, GL; Isaev, D; Isaeva, E; Krishtal, O; Lunko, O | 1 |
| Flores, JJ; Klebe, D; Krafft, PR; Lekic, T; McBride, DW; Rolland, WB; Zhang, JH | 1 |
| Dholakia, S; Fildes, JE; Friend, PJ | 1 |
| Gu, Z; Liu, J; Liu, Y; Su, L; Wang, Z; Xu, Q; Zhang, S | 1 |
| Amrouche, K; Jamin, C | 1 |
| Chen, SB; Gu, LQ; Huang, ZL; Huang, ZS; Li, D; Ou, TM; Shan, C; Tan, JH; Wang, CX; Wang, YQ; Yin, QK | 1 |
| Gray, NS; Hellwig, S; Liu, Y; Smithgall, TE; Tan, L; Weir, MC | 1 |
| Chen, H; Dong, Z; Fredimoses, M; Lee, MH; Liu, K; Liu, X; Shi, Y; Song, M | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU | 1 |
| Corriden, R; Griffin, JH; Gupta, N; Liu, R; Nizet, V; Pogliano, J; Pogliano, K; Shin, S; Sinha, R | 1 |
| Bu, W; Chang, G; Chang, S; Dai, B; Hou, J; Hu, L; Kong, Y; Lan, X; Shi, J; Tao, Y; Wang, Y; Wei, Q; Wu, H; Xiao, W; Xie, B; Xie, Y; Yang, G; Yu, D; Zheng, J | 1 |
| Cao, Y; Deng, X; Feng, C; Li, C; Li, G; Li, H; Li, S; Liu, L; Yu, D | 1 |
| Chen, XY; Jiang, JF; Zhong, DF | 1 |
| Choi, CI; Drucker, KL; Kleppe, L; Langley, MR; Scarisbrick, IA; Yoon, H | 1 |
| Katayama, K; Noguchi, K; Sugimoto, Y; Takami, M | 1 |
| Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP | 1 |
| Kaufman, TS; Larghi, EL; Vargas, DF | 1 |
| Al Kury, LT; Bogovyk, R; Fedoriuk, M; Isaeva, E; Krishtal, O; Nikolaienko, O; Savotchenko, A; Semenikhina, M | 1 |
| Alessandri, B; Jussen, D; Kempski, O; Krämer, TJ; Krenzlin, H; Sakas, W | 1 |
| Abedini, S; Pasdar, A; Rivandi, M; Sahebkar, A; Tajbakhsh, A | 1 |
| Ahn, SY; Chang, YS; Park, WS; Sung, DK; Sung, SI | 1 |
| Rongrong, S; Sun, S; Xiaowu, L; Yangmei, Z; Youwei, Z; Yuan, Y | 1 |
| Benninger, F; Lenz, M; Maggio, N; Neufeld, MY; Shavit-Stein, E; Shimon, MB; Vlachos, A | 1 |
| Bai, M; Dong, Y; Han, S; Ma, J; Sun, X; Zhou, C | 1 |
| Lang, L; Shay, C; Teng, Y; Wang, X; Xiong, Y; Zhao, X | 1 |
| Azmoon, P; Banki, MA; Gonias, SL; Kounnas, MZ; Mantuano, E; Marchese, C; Pontecorvi, P; Zalfa, C; Zampieri, C | 1 |
| Li, Z; Min, W; Ni, W; Pierce, RW; Yin, M; Zhang, H; Zhou, HJ | 1 |
| Han, C; He, L; Lei, D; Li, S; Liu, L; Ma, T; Wen, S; Xie, S; Zhou, H | 1 |
| Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R | 1 |
| Ciraci, V; De Franchis, V; Fabrizi, C; Familiari, G; Familiari, P; Fumagalli, L; Leone, S; Matassa, R; Pompili, E; Tata, AM | 1 |
| Almengló, C; Álvarez, E; González-Juanatey, JR; González-Peteiro, M; Mosquera-Garrote, N | 1 |
| Hanada, K; Itoh, K; Kato, T; Kawamura, Y; Kitayama, K; Kudo, N; Miura, N; Nakata, M; Narita, M; Nozaka, M; Tatara, Y; Tomita, H; Toyama, Y; Tsushima, M; Yokono, Y | 1 |
| Bratton, BP; Gitai, Z; Kim, H; Li, SH; Martin, JK; Mateus, A; Moore, GM; Rabinowitz, JD; Savitski, MM; Sheehan, JP; Typas, A; Wilson, MZ | 1 |
| Lu, X; Luo, S; Pang, C; Qin, H; Wen, L; Zhu, B | 1 |
| Andreae, EA; Twining, SS; Warejcka, DJ | 1 |
| Chen, B; Guan, YX; Huang, W; Jing, F; Ma, Q; Wu, CJ; Xu, SJ | 1 |
| Javle, M; King, G | 1 |
| Albert, V; Brockhoff, G; Gaumann, A; Hummel, M; Jagla, W; Lammert, H; Ortmann, O; Piendl, G; Wege, AK; Yousseff, D | 1 |
91 review(s) available for quinazolines and pyrroles
| Article | Year |
|---|---|
The quinazoline alkaloids.
Topics: Alkaloids; Animals; Chemical Phenomena; Chemistry; Indoles; Pyridines; Pyrroles; Quinazolines | 1984 |
Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Drug Design; Folic Acid; Folic Acid Antagonists; Glutamates; Guanine; Humans; Hydroxymethyl and Formyl Transferases; Indicators and Reagents; Molecular Structure; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Pyrroles; Quinazolines; Structure-Activity Relationship; Tetrahydrofolates | 1993 |
The structure-based design of ATP-site directed protein kinase inhibitors.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Anthraquinones; Binding Sites; Catalytic Domain; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Humans; Kinetin; Piperazines; Protein-Tyrosine Kinases; Purines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Growth Factor; Roscovitine; Staurosporine; Structure-Activity Relationship | 1999 |
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2001 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Antitumor activity of HER-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
JAK protein kinase inhibitors.
Topics: Animals; Drug Design; Enzyme Inhibitors; Forecasting; Gene Expression Regulation; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Mannich Bases; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; TYK2 Kinase | 2005 |
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Anti-angiogenic and anti-HER therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Molecularly targeted therapy in breast cancer: the new generation.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Medicinal chemistry strategies in follow-on drug discovery.
Topics: Animals; Atorvastatin; Bendamustine Hydrochloride; Benzazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Delivery Systems; Drug Discovery; gamma-Aminobutyric Acid; Heptanoic Acids; Humans; Lapatinib; Nitrogen Mustard Compounds; Pregabalin; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides | 2009 |
Recent advances in the development of P-gp inhibitors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coumarins; Drug Design; Drug Resistance, Neoplasm; Flavonoids; Humans; Peptides; Propafenone; Propanolamines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Structure-Activity Relationship; Tamoxifen; Terpenes; Verapamil | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Topics: Animals; Clinical Trials as Topic; Graft Rejection; Humans; Organ Transplantation; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines | 2009 |
AEB071--a promising immunosuppressive agent.
Topics: Clinical Trials as Topic; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Novel immunosuppressive agents in kidney transplantation.
Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Everolimus; Graft Rejection; Graft Survival; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Recombinant Fusion Proteins; Sirolimus | 2010 |
Overview of sotrastaurin clinical pharmacokinetics.
Topics: Biomarkers; Drug Interactions; Drug Monitoring; Graft Rejection; Humans; Immunosuppressive Agents; Lymphocyte Activation; Organ Transplantation; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; T-Lymphocytes | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Topics: Calcineurin Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sirolimus; Tacrolimus; Treatment Outcome | 2011 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Current landscape for T-cell targeting in autoimmunity and transplantation.
Topics: Autoimmune Diseases; Calcineurin Inhibitors; Cell Differentiation; Cell Proliferation; Cytokines; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Organ Transplantation; Piperidines; Protein Kinase C; Pyrimidines; Pyrroles; Quinazolines; Receptors, Cytokine; T-Lymphocytes; Transplantation Immunology; Transplantation Tolerance | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Renal-sparing regimens employing new agents.
Topics: Abatacept; Calcineurin Inhibitors; Cyclosporine; Everolimus; Graft Rejection; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney; Kidney Transplantation; Mycophenolic Acid; Pyrroles; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Topics: Abatacept; Calcineurin Inhibitors; Everolimus; Humans; Immunoconjugates; Immunosuppression Therapy; Liver Transplantation; Mycophenolic Acid; Precision Medicine; Pyrroles; Quinazolines; Renal Insufficiency; Risk Factors; Sirolimus; Tacrolimus; TOR Serine-Threonine Kinases | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Topics: Abatacept; Animals; Calcineurin Inhibitors; Drug Therapy, Combination; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Molecular Targeted Therapy; Organ Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Risk Assessment; Risk Factors; Signal Transduction; Time Factors; Treatment Outcome | 2016 |
Synthetic Strategies for 5- and 6-Membered Ring Azaheterocycles Facilitated by Iminyl Radicals.
Topics: Catalysis; Cyclization; Dioxoles; Free Radicals; Indole Alkaloids; Oximes; Phenanthridines; Pyridines; Pyrroles; Quinazolines; Quinones | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
The use of kinase inhibitors in solid organ transplantation.
Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase | 2017 |
Influence of drug molecules on regulatory B cells.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B-Cell Activating Factor; B-Lymphocytes, Regulatory; CD40 Antigens; Cytokines; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Pyrroles; Quinazolines; Receptors, Antigen, B-Cell; Semaphorins; Sirolimus; Toll-Like Receptors; Tretinoin; Vitamin D; Vitamins | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
[Metabolic research of domestically developed small molecule tyrosine kinase inhibitors].
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Benzofurans; China; Crown Ethers; Drug Interactions; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines | 2016 |
The 6π-azaelectrocyclization of azatrienes. Synthetic applications in natural products, bioactive heterocycles, and related fields.
Topics: Alkaloids; Aza Compounds; Biological Products; Chemistry Techniques, Synthetic; Cyclization; Histamine Agonists; Piperidines; Pyridines; Pyrroles; Quinazolines; Quinolizines; Sesquiterpenes | 2019 |
Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review.
Topics: Anoikis; Berberine; Chlorobenzoates; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrans; Pyrroles; Quinazolines; Saponins; Signal Transduction; Styrenes; Triple Negative Breast Neoplasms | 2019 |
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Mutation; Phenylurea Compounds; Precision Medicine; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction | 2021 |
23 trial(s) available for quinazolines and pyrroles
| Article | Year |
|---|---|
Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.
Topics: Adult; Aged; Biopsy; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Tacrolimus; Treatment Outcome | 2010 |
Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Everolimus; Humans; Immunosuppressive Agents; Male; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sirolimus; Young Adult | 2010 |
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
Topics: Adult; Area Under Curve; Biomarkers; Calcium; Cell Proliferation; Cross-Over Studies; Drug Interactions; Humans; Immunosuppressive Agents; Interleukin-2; Lymphocyte Activation; Lymphocytes; Male; Protein Kinase C; Pyrroles; Quinazolines; RNA, Messenger; T-Lymphocytes; Tacrolimus; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
Sotrastaurin and cyclosporine drug interaction study in healthy subjects.
Topics: Adult; Biomarkers, Pharmacological; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Lymphocyte Activation; Male; Pyrroles; Quinazolines; T-Lymphocytes | 2010 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Quinazolines; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients.
Topics: Female; Graft Rejection; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Protein Kinase C; Pyrroles; Quinazolines | 2011 |
Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Longitudinal Studies; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Pyrroles; Quinazolines; Tacrolimus; Treatment Outcome; Young Adult | 2011 |
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.
Topics: Adult; Calcineurin Inhibitors; Female; Humans; Kidney Transplantation; Male; Mycophenolic Acid; Protein Kinase C; Pyrroles; Quinazolines; Tacrolimus | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.
Topics: Acute Disease; Adult; Antineoplastic Agents; Biopsy; Calcineurin Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sirolimus; Transplantation, Homologous; Treatment Outcome | 2013 |
Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
Topics: Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Immunosuppressive Agents; Kidney; Kidney Transplantation; Pyrroles; Quinazolines; Retrospective Studies; Tacrolimus; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
The protein kinase C inhibitor sotrastaurin allows regulatory T cell function.
Topics: Adult; CD4 Antigens; Cell Proliferation; Cyclosporine; Female; Flow Cytometry; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Kidney Transplantation; Lymphocyte Count; Lymphocyte Culture Test, Mixed; Male; Middle Aged; NF-kappa B; Phosphorylation; Protein Kinase C; Pyrroles; Quinazolines; Signal Transduction; STAT5 Transcription Factor; T-Lymphocytes, Regulatory | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial.
Topics: Adult; Aged; Biopsy; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Kidney Transplantation; Liver Failure; Liver Transplantation; Male; Middle Aged; Protein Kinase C; Pyrroles; Quinazolines; Tacrolimus; Time Factors; Treatment Outcome | 2015 |
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Topics: Adult; Aged; Autoantibodies; Benzimidazoles; Central Serous Chorioretinopathy; Cross-Sectional Studies; Drug Combinations; Electrooculography; Electroretinography; Eye Proteins; Female; Fluorescein Angiography; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prospective Studies; Protein Kinase C; Pyrroles; Quinazolines; Skin Neoplasms; Subretinal Fluid; Tomography, Optical Coherence; Uveal Neoplasms; Visual Acuity | 2015 |
246 other study(ies) available for quinazolines and pyrroles
| Article | Year |
|---|---|
[Research on substances with antiblastic activity. LXII. Synthesis and antineoplastic activity of pyrrolo-[2,1-b] quinazoline derivatives and of 4H-pyrrolo[2,1-b] [1,3] benzodiazepine derivatives].
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Drug Evaluation, Preclinical; Leukemia L1210; Mice; Pyrroles; Quinazolines | 1978 |
[On the variability of substances contained in the goat's rue (Galega officinalis L.)].
Topics: Chromatography, Paper; Guanidines; Plants, Medicinal; Pyrroles; Quinazolines | 1967 |
General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors.
Topics: Animals; Binding Sites; Chemical Phenomena; Chemistry, Physical; Crystallography; Folic Acid Antagonists; Liver; Models, Chemical; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Rats; Structure-Activity Relationship; Triazines | 1984 |
Preparation of specific antibody to 2,3-trimethylene-4-quinazolone for the immunoassay of delta 1-pyrroline.
Topics: Animals; Antibody Formation; Antibody Specificity; Female; Haptens; Immunochemistry; Pyrroles; Quinazolines; Rabbits | 1980 |
Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Babesiosis; Cricetinae; Drug Evaluation, Preclinical; Mesocricetus; Pyrroles; Quinazolines | 1997 |
The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration.
Topics: Administration, Oral; Animals; Antidotes; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Dogs; Folic Acid Antagonists; Half-Life; Infusions, Intravenous; Leucovorin; Male; Pyrroles; Quinazolines; Rats; Rats, Inbred Strains; Species Specificity | 1997 |
Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists.
Topics: Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; Structure-Activity Relationship; Thrombin | 1999 |
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
Topics: Animals; Calcium; Carbazoles; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guinea Pigs; Heart Atria; Heart Rate; Hydrazines; Indoles; Isoquinolines; Male; Milrinone; Models, Biological; Molsidomine; Nitric Oxide Donors; Nitrogen Oxides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Ryanodine; Sarcoplasmic Reticulum; Signal Transduction; Spectrometry, Fluorescence; Sulfonamides; Superoxide Dismutase; Tetrahydroisoquinolines; Thionucleotides; Time Factors; Vasodilator Agents | 2000 |
Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
Topics: Apoptosis Regulatory Proteins; Bacterial Proteins; Blood Platelets; Calcium; Carrier Proteins; Cells, Cultured; DNA; Humans; Intracellular Signaling Peptides and Proteins; Muscle, Smooth, Vascular; P-Selectin; Peptide Fragments; Platelet Aggregation; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; RNA-Binding Proteins; Thrombin; Thymidine; Transcription Factors; Triallate | 2000 |
Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antithrombins; Binding Sites, Antibody; Blood Platelets; Calcium; Calcium Signaling; Cytoplasmic Granules; Elapid Venoms; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Kinetics; Metalloendopeptidases; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; Serine Proteinase Inhibitors; Sulfones; Thrombin | 2001 |
A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Female; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Mice; Monocytes; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrroles; Quinazolines; Quinolines; Sheep | 2002 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors | 2003 |
Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects.
Topics: Amino Acid Sequence; Animals; Cardiovascular Abnormalities; ErbB Receptors; Humans; Molecular Sequence Data; Pyrimidines; Pyrroles; Quinazolines; Rats; Tyrphostins; Zebrafish | 2003 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |
Regioselective quinazolinone-directed ortho lithiation of quinazolinoylquinoline: practical synthesis of naturally occurring human DNA topoisomerase I poison luotonin a and luotonins B and E.
Topics: Enzyme Inhibitors; Humans; Lithium; Molecular Structure; Pyrroles; Quinazolines; Quinones; Stereoisomerism; Topoisomerase I Inhibitors | 2004 |
Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
Topics: Cell Division; Cells, Cultured; Endothelium, Vascular; ErbB Receptors; Humans; Molecular Mimicry; Pyrroles; Quinazolines; Structure-Activity Relationship; Triazines; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab | 2005 |
Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.
Topics: Animals; Antimalarials; Disease Models, Animal; Malaria; Mice; Plasmodium berghei; Plasmodium falciparum; Pyrroles; Quinazolines | 2005 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Rhodium-catalyzed direct C-H addition of 3,4-dihydroquinazolines to alkenes and their use in the total synthesis of vasicoline.
Topics: Alkenes; Catalysis; Cyclization; Pyrroles; Quinazolines; Rhodium | 2006 |
Pharmacological characterization of protease activated receptor-1 by a serum responsive element-dependent reporter gene assay: major role of calmodulin.
Topics: Animals; Binding, Competitive; Biological Assay; Calcium-Calmodulin-Dependent Protein Kinases; Calmodulin; Chlorocebus aethiops; COS Cells; Egtazic Acid; Genes, Reporter; GTP-Binding Protein alpha Subunits; Ligands; Luciferases; Oligopeptides; Pyrroles; Quinazolines; Radioligand Assay; Receptor, PAR-1; RGS Proteins; Serum Response Element; Sesterterpenes; Sulfonamides; Terpenes; Thrombin; Transfection | 2006 |
PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration.
Topics: Cell Line, Tumor; Cell Movement; Dipeptides; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Oligopeptides; Phosphorylation; Pyrroles; Quinazolines; Receptor, PAR-1; Thrombin; Tyrosine; Tyrphostins | 2006 |
Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Chick Embryo; Dose-Response Relationship, Drug; Endothelial Cells; Neovascularization, Physiologic; Pyrroles; Quinazolines; Receptor, PAR-1 | 2006 |
New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Malaria; Maximum Tolerated Dose; Parasitemia; Plasmodium berghei; Prodrugs; Pyrroles; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Therapeutic Equivalency | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Topics: Blood Platelets; Crotalid Venoms; Dose-Response Relationship, Drug; Drug Synergism; Humans; In Vitro Techniques; Indazoles; Oligopeptides; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; Thrombin; Urea | 2006 |
Mesotrypsin, a brain trypsin, activates selectively proteinase-activated receptor-1, but not proteinase-activated receptor-2, in rat astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; Brain Chemistry; Calcium; Cells, Cultured; Cytosol; Isoenzymes; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Receptor, PAR-2; Recombinant Proteins; Retinal Ganglion Cells; Trypsin | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoproteins; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
Radical reactions with 3H-quinazolin-4-ones: synthesis of deoxyvasicinone, mackinazolinone, luotonin A, rutaecarpine and tryptanthrin.
Topics: Alkaloids; Cyclization; Free Radicals; Indole Alkaloids; Molecular Structure; Pyrroles; Quinazolines; Quinazolinones; Quinones | 2007 |
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2007 |
SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Topics: Androstadienes; Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glyburide; Hirudins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Oligopeptides; omega-N-Methylarginine; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Potassium Channel Blockers; Potassium Channels; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Recombinant Proteins; Research Design; RNA, Messenger; Signal Transduction; Thrombin; Time Factors; Ventricular Function, Left; Wortmannin | 2007 |
Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats.
Topics: Administration, Oral; Animals; Anorexia; Antimalarials; Biological Availability; Hydrolysis; Male; Maximum Tolerated Dose; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley | 2007 |
Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mice; Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Receptor, PAR-1 | 2007 |
VEGF modulation of retinal pigment epithelium resistance.
Topics: Animals; Cell Line; Cell Membrane Permeability; Cells, Cultured; Dose-Response Relationship, Drug; Electric Impedance; Humans; Indoles; Pigment Epithelium of Eye; Pyrroles; Quinazolines; Retina; Sus scrofa; Tight Junctions; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Comments on "Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis".
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Proliferation; Chick Embryo; Endothelial Cells; Humans; Indazoles; Neovascularization, Physiologic; Pyrroles; Quinazolines; Receptor, PAR-1; Urea | 2008 |
The specificity of JAK3 kinase inhibitors.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Enzyme Inhibitors; Graft Rejection; Humans; Janus Kinase 3; Kinetics; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2008 |
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Topics: Afferent Pathways; Animals; Animals, Newborn; Dose-Response Relationship, Radiation; Drug Interactions; Electric Stimulation; Epilepsy; Glutamic Acid; Hemostatics; Hippocampus; Long-Term Potentiation; Male; Peptide Fragments; Potassium; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Thrombin | 2008 |
CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
Topics: Binding Sites; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrroles; Quantitative Structure-Activity Relationship; Quinazolines | 2008 |
One-pot synthesis of simple alkaloids: 2,3-polymethylene-4(3H)-quinazolinones, luotonin A, tryptanthrin, and rutaecarpine.
Topics: Chemical Phenomena; Chemistry, Physical; Indicators and Reagents; Indole Alkaloids; Lactams; Magnetic Resonance Spectroscopy; ortho-Aminobenzoates; Pyrroles; Quinazolines; Quinazolinones; Quinones; Spectrophotometry, Infrared | 2008 |
Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp.
Topics: Adult; Calcium; Cells, Cultured; Dental Pulp; Dinoprostone; Fibrinolysin; Humans; Inflammation; Interleukin-8; Peptides; Pyrroles; Quinazolines; Receptor, PAR-1; RNA, Messenger | 2008 |
Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation.
Topics: Acyltransferases; Animals; Arachidonic Acid; Arachidonic Acids; Cattle; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Fatty Acids; Group IV Phospholipases A2; Humans; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phospholipids; Pyrroles; Quinazolines; Receptor, PAR-1; RNA, Messenger; Thimerosal; Thrombin; Time Factors | 2008 |
Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes.
Topics: Animals; Astrocytes; Cells, Cultured; Encephalitis; Enzyme Activation; Enzyme Inhibitors; Extracellular Matrix; Flavonoids; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase 3; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Thrombin | 2008 |
Amyloid beta peptide-activated signal pathways in human platelets.
Topics: Amyloid beta-Peptides; Blood Platelets; Enzyme Activation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 8; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Aggregation; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Receptor, PAR-1; Receptor, PAR-2; Signal Transduction | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The periodontal pathogen Porphyromonas gingivalis sensitises human blood platelets to epinephrine.
Topics: Adhesins, Bacterial; Apyrase; Aspirin; Blood Platelets; Calcium Signaling; Cyclooxygenase Inhibitors; Cysteine Endopeptidases; Epinephrine; Gingipain Cysteine Endopeptidases; Humans; In Vitro Techniques; Leupeptins; Nephelometry and Turbidimetry; Oligopeptides; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Porphyromonas gingivalis; Protease Inhibitors; Pyrroles; Quinazolines; Receptors, Proteinase-Activated; Virulence; Yohimbine | 2008 |
Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.
Topics: Cells, Cultured; Chemistry, Pharmaceutical; Drug Carriers; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Kinetics; Muramidase; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2008 |
Role of protease-activated receptor-1 in endothelial nitric oxide synthase-Thr495 phosphorylation.
Topics: ADP Ribose Transferases; Amides; Botulinum Toxins; Cells, Cultured; Endothelial Cells; Genes, Dominant; Humans; Models, Biological; Nitric Oxide Synthase Type III; Nitrites; Oligopeptides; Phosphorylation; Phosphothreonine; Pyridines; Pyrroles; Quinazolines; Receptor, PAR-1; Receptor, PAR-2; rho-Associated Kinases; rhoA GTP-Binding Protein; Thrombin; Umbilical Veins | 2009 |
Growth factors involved in aqueous humour-induced lens cell proliferation.
Topics: Animals; Aqueous Humor; Cell Proliferation; Cells, Cultured; Epidermal Growth Factor; Epithelial Cells; Fibroblast Growth Factors; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Lens, Crystalline; Platelet-Derived Growth Factor; Pyrroles; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins | 2009 |
B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.
Topics: Antineoplastic Agents; Bromodeoxyuridine; CDC2 Protein Kinase; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; G2 Phase; Humans; Imidazoles; Indoles; Mitosis; Pyrroles; Quinazolines | 2010 |
PAR1 antagonist mediated antithrombotic activity in extracorporeal arterio-venous shunt in the rat.
Topics: Animals; Arteriovenous Shunt, Surgical; Fibrinolytic Agents; Isoindoles; Male; Pyrroles; Quinazolines; Rats; Rats, Inbred Strains; Receptor, PAR-1 | 2010 |
The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
Topics: Animals; Calcium; CD28 Antigens; Cell Adhesion; Cytokines; Electrophoretic Mobility Shift Assay; Flow Cytometry; Genes, Reporter; Humans; Immunosuppressive Agents; Isoenzymes; Jurkat Cells; Macrophage Activation; Mice; Mice, Knockout; NF-kappa B; NFATC Transcription Factors; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocytes | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib | 2010 |
Coagulation factor Xa activates thrombin in ischemic neural tissue.
Topics: Animals; Animals, Newborn; Anticoagulants; Cell Death; Factor Xa; Fondaparinux; Gene Expression Regulation; Glucose; Hippocampus; Hypoxia; Ischemia; JNK Mitogen-Activated Protein Kinases; Organ Culture Techniques; Polysaccharides; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Serine; Signal Transduction; Thrombin | 2009 |
Thrombin induces cyclooxygenase-2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages.
Topics: Animals; Cell Line; Cyclooxygenase 2; Dinoprostone; Enzyme Induction; Enzyme Inhibitors; Epoprostenol; Flavonoids; Imidazoles; Macrophages, Peritoneal; Mice; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Pyridines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Thrombin; Thromboxane A2 | 2009 |
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
Topics: Administration, Oral; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Half-Life; Humans; Immunosuppressive Agents; Ketoconazole; Male; Pyrroles; Quinazolines; Young Adult | 2009 |
Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGFbeta3) production/secretion through proteinase-activated receptor-1 (PAR-1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB si
Topics: Analysis of Variance; Animals; Astrocytes; Blotting, Western; Cells, Cultured; Chromones; Culture Media, Conditioned; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolysin; Fibrinolytic Agents; Fibroblast Growth Factors; Flavonoids; Immunohistochemistry; Microglia; Morpholines; Nerve Growth Factors; Neurons; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasminogen; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta3 | 2009 |
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.
Topics: Binding Sites; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Hydrogen Bonding; Indoles; Ligands; Models, Molecular; Oxindoles; Propionates; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrroles; Quinazolines; Reproducibility of Results; Sunitinib | 2009 |
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Cell Death; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Indoles; Lapatinib; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2009 |
Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
Topics: Animals; Clinical Trials as Topic; Drug Discovery; Humans; Isoenzymes; Maleimides; Mice; Models, Molecular; Molecular Conformation; Molecular Weight; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Rats; Substrate Specificity; T-Lymphocytes; Transplantation Tolerance | 2009 |
Autophagy can contribute to cell death when combining targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Colonic Neoplasms; HCT116 Cells; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2009 |
beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling.
Topics: Animals; beta Catenin; beta-Galactosidase; Cell Polarity; Cell Proliferation; Down-Regulation; Genetic Complementation Test; Glycogen Synthase Kinase 3; Humans; Jurkat Cells; Mice; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Signal Transduction; TCF Transcription Factors; Transcription, Genetic; Transgenes; Wnt Proteins; Wnt-5a Protein; Wnt3 Protein; Wnt3A Protein | 2010 |
Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Topics: Animals; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Fingolimod Hydrochloride; Heart Transplantation; Immunosuppressive Agents; Male; Propylene Glycols; Protein Kinase C; Pyrroles; Quinazolines; Rats; Rats, Inbred Lew; Rats, Wistar; Sirolimus; Sphingosine | 2010 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.
Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms | 2010 |
Effects of the new immunosuppressive agent AEB071 on human immune cells.
Topics: CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Cytokines; Dendritic Cells; Humans; Immunosuppressive Agents; Ionomycin; K562 Cells; Killer Cells, Natural; Leukocytes, Mononuclear; Protein Kinase C; Pyrroles; Quinazolines; Tetradecanoylphorbol Acetate | 2010 |
Bioactivity and molecular targets of novel substituted quinolines in murine and human tumor cell lines in vitro.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Epidermal Growth Factor; Ethidium; Gap Junctions; HSP90 Heat-Shock Proteins; Humans; Mice; Nucleosides; Pyrroles; Quinazolines; Quinolines; Signal Transduction | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Topics: Angiogenesis Inhibitors; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; DNA-Directed DNA Polymerase; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indoles; Phenylurea Compounds; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Vascular Endothelial Growth Factor A | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report.
Topics: Animals; Graft Rejection; Graft Survival; Heart Transplantation; Lymphocyte Activation; Male; Myocardial Contraction; Pyrroles; Quinazolines; Rats; Rats, Inbred BN; Rats, Inbred Lew; T-Lymphocytes; Tacrolimus; Transplantation, Heterotopic; Transplantation, Homologous | 2010 |
Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
Topics: Animals; Guinea Pigs; Humans; Inhibitory Concentration 50; Isoindoles; Male; Models, Animal; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Receptor, PAR-1; Species Specificity; Thrombin Time | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Effect of enteropeptidase on survival of cultured hippocampal neurons under conditions of glutamate toxicity.
Topics: Animals; Cattle; Cell Survival; Cells, Cultured; Enteropeptidase; Glutamic Acid; Hippocampus; Humans; Neurons; Pyrroles; Quinazolines; Receptor, PAR-1; Recombinant Proteins; Thrombin | 2010 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
One-pot synthesis of luotonin A and its analogues.
Topics: DNA Topoisomerases, Type I; Humans; Molecular Structure; Peganum; Pyrroles; Quinazolines; Quinolines; Quinones; Topoisomerase I Inhibitors | 2011 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Topics: Animals; CARD Signaling Adaptor Proteins; CD79 Antigens; Cell Growth Processes; Cell Line, Tumor; G1 Phase; Guanylate Cyclase; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mutation; NF-kappa B; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrroles; Quinazolines; Signal Transduction | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult | 2011 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Activation of cumulus cell SMAD2/3 and epidermal growth factor receptor pathways are involved in porcine oocyte-cumulus cell expansion and steroidogenesis.
Topics: Animals; Benzamides; C-Reactive Protein; Cell Adhesion Molecules; Cumulus Cells; Dioxoles; Epidermal Growth Factor; ErbB Receptors; Female; Follicle Stimulating Hormone; Gene Expression Regulation, Developmental; Glucuronosyltransferase; Hyaluronic Acid; Isoquinolines; Meiosis; Mice; Oocytes; Progesterone; Pyridines; Pyrroles; Quinazolines; Serum Amyloid P-Component; Signal Transduction; Smad2 Protein; Smad3 Protein; Swine; Tyrphostins | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
The search for CNI-free immunosuppression: no free lunch.
Topics: Female; Humans; Kidney Transplantation; Male; Protein Kinase C; Pyrroles; Quinazolines | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.
Topics: Animals; Cells, Cultured; Graft Rejection; Humans; Lymphocyte Activation; Macaca fascicularis; Mice; Mice, Inbred BALB C; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Rats; Structure-Activity Relationship; Tissue Distribution | 2011 |
The effects of AEB071 (sotrastaurin) with tacrolimus on rat heterotopic cardiac allograft rejection and survival.
Topics: Acute Disease; Animals; Disease Models, Animal; Drug Therapy, Combination; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Kidney; Liver; Male; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Rats; Rats, Inbred BN; Rats, Inbred Lew; Tacrolimus; Transplantation, Heterotopic; Transplantation, Homologous | 2011 |
Proteinase-activated receptors 1 and 2 exert opposite effects on renal renin release.
Topics: Adrenergic beta-Agonists; Animals; Dose-Response Relationship, Drug; Isoproterenol; Juxtaglomerular Apparatus; Kidney; Male; Mice; Mice, Inbred C57BL; Models, Animal; Nitric Oxide; Oligopeptides; Pyrroles; Quinazolines; Receptor, PAR-1; Receptor, PAR-2; Renin; Thrombin | 2011 |
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration | 2012 |
Sotrastaurin, a protein kinase C inhibitor, ameliorates ischemia and reperfusion injury in rat orthotopic liver transplantation.
Topics: Animals; Apoptosis; Cell Proliferation; Cold Ischemia; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Liver Transplantation; Male; NF-kappa B; Protein Kinase C; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction; T-Lymphocytes | 2011 |
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus.
Topics: Calcineurin; Calcineurin Inhibitors; Cell Line, Tumor; Cyclosporine; Hepacivirus; Hepatitis B virus; Humans; Immunosuppressive Agents; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; RNA, Viral; Virus Internalization; Virus Replication | 2011 |
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish | 2011 |
The effect of epigenetic factors on differentiation of pancreatic progenitor cells into insulin-producing cells.
Topics: Azacitidine; Azepines; C-Peptide; Cell Culture Techniques; Cell Differentiation; Decitabine; Epigenesis, Genetic; Humans; Hydroxamic Acids; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Keratin-19; Models, Biological; Models, Genetic; Pancreas; Pyrroles; Quinazolines; Stem Cells; Transcription Factors | 2011 |
Sotrastaurin, a new selective protein kinase C inhibitor, on the way.
Topics: Animals; Cyclosporine; Graft Survival; Humans; Kidney Transplantation; Pyrroles; Quinazolines | 2012 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts.
Topics: Animals; Cyclosporine; Drug Synergism; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Activation; Macaca fascicularis; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; T-Lymphocytes; Time Factors; Transplantation, Homologous | 2012 |
Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
Topics: Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Genes, erbB-2; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2012 |
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
PKCθ: a new target for selective immunosuppression.
Topics: Animals; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppression Therapy; Isoenzymes; Mice; Mice, Knockout; Molecular Targeted Therapy; NF-kappa B; Protein Kinase C; Protein Kinase C-theta; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Signal Transduction; T-Lymphocytes | 2012 |
Synthesis and biological evaluation of (--)-linarinic acid derivatives as neuroprotective agents against OGD-induced cell damage.
Topics: Brain Ischemia; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Culture Media; Dose-Response Relationship, Drug; Glucose; Humans; Models, Biological; Molecular Structure; Neurons; Neuroprotective Agents; Oxygen; Pyrroles; Quinazolines; Reperfusion Injury; Stereoisomerism; Structure-Activity Relationship | 2012 |
Thrombin receptor regulates hematopoiesis and endothelial-to-hematopoietic transition.
Topics: Amides; Animals; Cell Differentiation; Cells, Cultured; Embryonic Stem Cells; Endothelial Cells; Flow Cytometry; Hematopoiesis; Hematopoietic Stem Cells; Mice; Pyridines; Pyrroles; Quinazolines; Receptors, Thrombin; rho-Associated Kinases; rhoA GTP-Binding Protein; Zebrafish | 2012 |
Validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of Sotrastaurin and its metabolite N-desmethyl-sotrastaurin in human blood.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Least-Squares Analysis; Pyrroles; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation.
Topics: Cell Proliferation; Cells, Cultured; Chromones; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Imidazoles; Morpholines; Myocytes, Smooth Muscle; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyridines; Pyrroles; Quinazolines; RNA, Small Interfering; Saphenous Vein; Thrombin | 2012 |
Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury.
Topics: Animals; Chemokine CXCL1; Creatinine; Kidney; Male; Neutrophil Infiltration; P-Selectin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2012 |
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Gene Expression; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Isoenzymes; MAP Kinase Signaling System; Melanoma; NF-kappa B; Phosphorylation; Protein Kinase C; Protein Processing, Post-Translational; Pyrroles; Quinazolines; Uveal Neoplasms | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Topics: Apoptosis; B-Lymphocytes; B7-1 Antigen; B7-2 Antigen; Cell Membrane; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Everolimus; Graft Rejection; Humans; Immunity, Humoral; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Immunosuppressive Agents; Interleukin-10; Leukocytes, Mononuclear; Mycophenolic Acid; Pyrroles; Quinazolines; Sirolimus; Transplantation, Homologous | 2012 |
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides | 2012 |
Detection and confirmation of alkaloids in leaves of Justicia adhatoda and bioinformatics approach to elicit its anti-tuberculosis activity.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Alkaloids; Antitubercular Agents; Computational Biology; Fatty Acid Synthase, Type II; Humans; Justicia; Molecular Docking Simulation; Mycobacterium tuberculosis; Plant Leaves; Pyrroles; Quinazolines; Tuberculosis | 2012 |
Protein kinase C inhibition ameliorates posttransplantation preservation injury in rat renal transplants.
Topics: Adenosine; Allopurinol; Animals; Apoptosis; Biomarkers; Blotting, Western; Cell Proliferation; Cold Temperature; Creatinine; Cytokines; Cytoprotection; Delayed Graft Function; Glutathione; Immunohistochemistry; Inflammation Mediators; Insulin; Kidney; Kidney Transplantation; Male; Mycophenolic Acid; Organ Preservation; Organ Preservation Solutions; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Raffinose; Rats; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Signal Transduction; Time Factors | 2012 |
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Female; HSP70 Heat-Shock Proteins; Humans; Indoles; Lapatinib; Membrane Proteins; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; p38 Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Reactive Oxygen Species | 2012 |
PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats.
Topics: Animals; Apoptosis; Blotting, Western; Brain; Brain Edema; Brain Injuries; Immunohistochemistry; Intraoperative Complications; Male; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 5; Neurosurgical Procedures; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Thrombin | 2013 |
Regulation of neuronal plasticity and fear by a dynamic change in PAR1-G protein coupling in the amygdala.
Topics: Amygdala; Animals; Conditioning, Classical; Excitatory Postsynaptic Potentials; Exploratory Behavior; Fear; Freezing Reaction, Cataleptic; GTP-Binding Protein alpha Subunits, Gq-G11; Guanosine 5'-O-(3-Thiotriphosphate); Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Knockout; Miniature Postsynaptic Potentials; Nerve Net; Nerve Tissue Proteins; Pain Threshold; Patch-Clamp Techniques; Pyrroles; Quinazolines; Receptor, PAR-1; Recognition, Psychology | 2013 |
Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
Topics: Angiogenic Proteins; Cell Proliferation; Humans; Indoles; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor A; Xanthones | 2012 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs.
Topics: Animals; Blood Platelets; Cell Shape; Dose-Response Relationship, Drug; Humans; Mice; Mice, Knockout; Phosphatidylserines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Receptor, PAR-1; Time Factors | 2013 |
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.
Topics: Animals; Arginine; Capillary Permeability; Catalytic Domain; Cells, Cultured; Drug Agonism; Endothelium, Vascular; HEK293 Cells; Humans; Mice; Models, Biological; Models, Molecular; Protein C; Proteolysis; Pyrroles; Quinazolines; Receptor, PAR-1 | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Molecular Docking Simulation; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1 | 2013 |
Thrombin regulation of synaptic plasticity: implications for physiology and pathology.
Topics: Animals; Biophysics; Dose-Response Relationship, Drug; Electric Stimulation; Endothelial Protein C Receptor; Fibrinolysin; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; N-Methylaspartate; Neurons; Patch-Clamp Techniques; Phosphopyruvate Hydratase; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Cell Surface; Thrombin | 2013 |
Combined standard and novel immunosuppressive substances affect B-lymphocyte function.
Topics: Apoptosis; B-Lymphocytes; B7-1 Antigen; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Everolimus; Humans; Immunity, Humoral; Immunoglobulin G; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mycophenolic Acid; Primary Cell Culture; Pyrroles; Quinazolines; Sirolimus | 2013 |
Role of SCH79797 in maintaining vascular integrity in rat model of subarachnoid hemorrhage.
Topics: Animals; Blood-Brain Barrier; Brain; Disulfides; Enzyme Inhibitors; Male; Naphthols; p21-Activated Kinases; Permeability; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Subarachnoid Hemorrhage | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Tacrolimus inhibits NF-κB activation in peripheral human T cells.
Topics: Calcineurin Inhibitors; Cells, Cultured; Cytokines; Humans; Immunosuppressive Agents; NF-kappa B; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Pyrroles; Quinazolines; Signal Transduction; T-Lymphocytes; Tacrolimus | 2013 |
Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Imaging, Three-Dimensional; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphorylation; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Transforming Growth Factor beta; Ventricular Remodeling | 2013 |
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
Topics: Adenomatous Polyps; Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinogenesis; Cell Proliferation; Chemoprevention; Colon; Colonic Neoplasms; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Female; Gefitinib; Heptanoic Acids; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pyrroles; Quinazolines | 2013 |
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib | 2013 |
Total synthesis of a pyrroloindoloquinazoline alkaloid.
Topics: Alkaloids; Cyclization; Indoles; Molecular Structure; Pyrroles; Quinazolines; Stereoisomerism | 2013 |
Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
Topics: Animals; Benzothiazoles; Connective Tissue Growth Factor; Endothelium, Vascular; ErbB Receptors; Fibroblasts; Fibrosis; Gene Expression Regulation; Isoquinolines; Mice; Mink; Myocytes, Smooth Muscle; Pyridines; Pyrroles; Quinazolines; Rats; Reactive Oxygen Species; Renal Insufficiency, Chronic; Serpin E2; Signal Transduction; Smad2 Protein; Smad3 Protein; Toluene; Transforming Growth Factor beta1; Tumor Suppressor Protein p53; Tyrphostins | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.
Topics: DNA Topoisomerases, Type I; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Molecular Docking Simulation; Protein Conformation; Pyrroles; Quinazolines; Topoisomerase I Inhibitors | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.
Topics: Adult; Aged; Allografts; Antibodies, Monoclonal; Azathioprine; Basiliximab; BK Virus; Cohort Studies; Cyclosporine; Female; Glomerular Filtration Rate; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Polyomavirus Infections; Proteinuria; Pyrroles; Quinazolines; Recombinant Fusion Proteins; Tacrolimus; Tumor Virus Infections; Viremia | 2014 |
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Inhibitory Concentration 50; MAP Kinase Kinase Kinases; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation, Missense; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Signal Transduction; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Topics: Cell Cycle Proteins; Cell Proliferation; Drug Design; HCT116 Cells; Humans; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Purines; Pyrimidines; Pyrroles; Quinazolines; Structure-Activity Relationship | 2013 |
Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.
Topics: Biopsy; CD28 Antigens; Cell Proliferation; Coculture Techniques; Cytokines; Forkhead Transcription Factors; Homeostasis; Humans; Interferon-gamma; Interleukin-17; Interleukin-1beta; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Protein Kinase C; Psoriasis; Pyrroles; Quinazolines; Skin; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Hydrocephalus after intraventricular hemorrhage: the role of thrombin.
Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Cerebral Ventricles; Hydrocephalus; Injections, Intraventricular; Magnetic Resonance Imaging; Male; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Thrombin | 2014 |
Reversal of trauma-induced amnesia in mice by a thrombin receptor antagonist.
Topics: Amnesia; Animals; Brain Injuries; Hippocampus; Long-Term Potentiation; Mice; Mice, Inbred ICR; Pyrroles; Quinazolines; Receptor, PAR-1; Thrombin | 2014 |
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Topics: Adenine; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence; Blotting, Western; CARD Signaling Adaptor Proteins; Cell Line; Cell Survival; DNA Primers; Guanylate Cyclase; Humans; Inhibitor of Apoptosis Proteins; Luminescent Measurements; Lymphoma, Mantle-Cell; Microarray Analysis; Molecular Sequence Data; NF-kappa B; NF-kappaB-Inducing Kinase; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA Interference; Sequence Analysis, RNA; Signal Transduction; TNF Receptor-Associated Factor 2; TNF Receptor-Associated Factor 3; Trypan Blue; Ubiquitin-Protein Ligases | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity.
Topics: Cell Death; Cell Line, Tumor; Human Umbilical Vein Endothelial Cells; Humans; Lysosomes; Mitochondria; Mitosis; Pyrroles; Quinazolines | 2014 |
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult | 2014 |
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Silencing; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyrroles; Quinazolines; RNA Interference; Signal Transduction; Thiazoles; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Proteinase-activated receptor 1 contributed to up-regulation of enkephalin in keratinocytes of patients with obstructive jaundice.
Topics: Adult; Animals; Bile Ducts; Blotting, Western; Cell Line; Electric Stimulation; Enkephalin, Methionine; Humans; Immunohistochemistry; Jaundice, Obstructive; Keratinocytes; Ligation; Liver; Male; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Pain Measurement; Pain Threshold; Pain, Postoperative; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptor, PAR-1; Thrombin; Up-Regulation | 2014 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1 | 2014 |
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
Topics: Apoptosis; beta Catenin; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase C beta; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Antigen, B-Cell; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Tumor Microenvironment; Wnt Signaling Pathway | 2014 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.
Topics: Albumins; Cell Differentiation; Cell Movement; Cells, Cultured; Cicatrix; Fibroblasts; Fibrosis; Humans; Interferon-gamma; Lactones; Leukocytes, Mononuclear; Monocytes; Pyridines; Pyrroles; Quinazolines; Receptor, PAR-1; Receptor, PAR-2; Serum Amyloid P-Component; Signal Transduction; Thrombin; Trypsin; Tryptases; Wound Healing | 2015 |
Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Endothelium, Vascular; Glutathione; Human Umbilical Vein Endothelial Cells; Humans; Oxidative Stress; Protein Kinase C beta; Pyrroles; Quinazolines; Reactive Oxygen Species; Taxoids | 2015 |
A 2D-DIGE-based proteomic analysis reveals differences in the platelet releasate composition when comparing thrombin and collagen stimulations.
Topics: Antibodies; Blood Platelets; Chromatography, High Pressure Liquid; Collagen; Humans; Platelet Aggregation; Protein S; Proteome; Proteomics; Pyrroles; Quinazolines; Tandem Mass Spectrometry; Thrombin; Two-Dimensional Difference Gel Electrophoresis; Up-Regulation | 2015 |
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Topics: Blotting, Western; Cell Line; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Luciferases; Microscopy, Fluorescence; Plasmids; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sunitinib; Virus Internalization | 2015 |
Sotrastaurin in liver transplantation: has it had a fair trial?
Topics: Enzyme Inhibitors; Female; Humans; Liver Failure; Liver Transplantation; Male; Protein Kinase C; Pyrroles; Quinazolines | 2015 |
Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and Ebp1.
Topics: Adaptor Proteins, Signal Transducing; Blotting, Western; Cell Proliferation; Cells, Cultured; DNA, Ribosomal; Gene Expression; Guanosine Triphosphate; HEK293 Cells; Humans; Jurkat Cells; Keratin-20; Lymphocyte Activation; Mutation; Mycophenolic Acid; Phosphorylation; Pol1 Transcription Initiation Complex Proteins; Proliferating Cell Nuclear Antigen; Promoter Regions, Genetic; Protein Binding; Protein Kinase C-delta; Pyrroles; Quinazolines; RNA Interference; RNA Polymerase I; RNA-Binding Proteins; RNA, Ribosomal; T-Lymphocytes | 2015 |
Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.
Topics: Animals; Body Weight; CA1 Region, Hippocampal; Male; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Status Epilepticus; Thrombin | 2015 |
[Erlotinib, sunitinib, and everolimus].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2015 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Hirudin promotes angiogenesis by modulating the cross-talk between p38 MAPK and ERK in rat ischemic skin flap tissue.
Topics: Animals; Endostatins; Hirudins; Humans; MAP Kinase Signaling System; Myocutaneous Flap; Neovascularization, Physiologic; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Quinazolines; Rats; Skin; Thrombospondins; Vascular Endothelial Growth Factor A | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; MCF-7 Cells; Mice; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
Topics: Airway Remodeling; Annexin A2; Asthma; Biopsy; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Factor Xa; Gene Expression Regulation; Humans; Integrin beta1; Myocytes, Smooth Muscle; Pyrroles; Quinazolines; Receptor, PAR-1; Respiratory System; RNA Interference; RNA, Messenger; Signal Transduction; Thrombin; Time Factors; Transfection | 2016 |
The Selective Estrogen Receptor Modulator Raloxifene Regulates Arginine-Vasopressin Gene Expression in Human Female Neuroblastoma Cells Through G Protein-Coupled Estrogen Receptor and ERK Signaling.
Topics: Arginine Vasopressin; Blotting, Western; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neuroblastoma; Phosphorylation; Protein Kinase C; Pyrroles; Quinazolines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Selective Estrogen Receptor Modulators | 2015 |
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; ErbB Receptors; Female; Gefitinib; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Signal Transduction | 2015 |
Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1.
Topics: Adult; Angiotensin II; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Matrix Metalloproteinase 1; Omentum; Organ Culture Techniques; Pre-Eclampsia; Pregnancy; Pyrroles; Quinazolines; Receptor, PAR-1; Vasoconstriction; Young Adult | 2016 |
Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Blotting, Western; Brain; Cyclooxygenase 2; Disease Models, Animal; Intracranial Hemorrhages; Oligopeptides; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Receptors, Thrombin | 2016 |
PAR-1, -4, and the mTOR Pathway Following Germinal Matrix Hemorrhage.
Topics: Animals; Animals, Newborn; Behavior, Animal; Blotting, Western; Brain; Immunosuppressive Agents; Intracranial Hemorrhages; Oligopeptides; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Receptors, Thrombin; Signal Transduction; Sirolimus; Thrombin; TOR Serine-Threonine Kinases | 2016 |
The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats.
Topics: Animals; Avoidance Learning; Benzothiazoles; Cholinesterase Inhibitors; Disease Models, Animal; Dizocilpine Maleate; Donepezil; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Histamine H3 Antagonists; Indans; Male; Memory; Memory Disorders; Nootropic Agents; Phenoxypropanolamines; Piperidines; Pyrilamine; Pyrroles; Quinazolines; Random Allocation; Rats, Wistar; Receptors, Histamine H3 | 2016 |
Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Flavonoids; Humans; Integrin beta1; Isoflavones; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phorbol Esters; Protein Kinase C-alpha; Pyrroles; Quinazolines; Signal Transduction | 2015 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA).
Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Fluorescence Resonance Energy Transfer; Gefitinib; Indoles; Lapatinib; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrroles; Quinazolines; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Thermodynamics | 2015 |
Kallikrein Promotes Inflammation in Human Dental Pulp Cells Via Protease-Activated Receptor-1.
Topics: Cells, Cultured; Complement C3; Dental Pulp; Enkephalins; Humans; Inflammation; Kallikreins; Prostate-Specific Antigen; Protein Precursors; Pulpitis; Pyrroles; Quinazolines; Receptor, PAR-1; Renin | 2016 |
Applications of Receptor- and Ligand-based Models in Inverse Docking Experiments: Recognition of Dihydrofolate Reductase Using 7,8-Dialkyl- 1,3-Diaminopyrrolo[3,2-f]Quinazolines.
Topics: Candida albicans; Candidiasis; Folic Acid Antagonists; Humans; Ligands; Molecular Docking Simulation; Protein Binding; Pyrroles; Quinazolines; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2016 |
Targeting protein kinase C in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Molecular Targeted Therapy; Phosphorylation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Tumor Cells, Cultured | 2016 |
Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Topics: Adult; Antibodies; Cohort Studies; Drug Interactions; Drug Substitution; Everolimus; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Pyrroles; Quinazolines; Tacrolimus | 2016 |
Pravastatin and C reactive protein modulate protease- activated receptor-1 expression in vitro blood platelets.
Topics: Adenosine Diphosphate; Blood Platelets; C-Reactive Protein; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Humans; Immunoblotting; P-Selectin; Platelet Aggregation; Pravastatin; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thromboxane A2, Prostaglandin H2; Scavenger Receptors, Class E; Thrombin | 2016 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; Female; Fibrinolytic Agents; Fibroblasts; Fibrosis; Goats; Heart Atria; Indazoles; Mice, Transgenic; Nadroparin; Peptide Hydrolases; Pyrroles; Quinazolines; Rats; Receptors, Thrombin; Thrombin; Thrombophilia; Urea | 2017 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Enzyme Inhibitors; Everolimus; Humans; Isoquinolines; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-mdm2; Pyrroles; Quinazolines; Tumor Suppressor Protein p53; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.
Topics: Amnesia; Analysis of Variance; Animals; Avoidance Learning; Cholinesterase Inhibitors; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Histamine H3 Antagonists; Male; Pyrroles; Pyrrolidines; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Scopolamine | 2016 |
Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Topics: Acetylation; Animals; Antiviral Agents; Bryostatins; Carbazoles; Cell Line; Chikungunya virus; Chlorocebus aethiops; Drug Design; Drug Synergism; Gene Expression Regulation, Viral; Humans; Isoenzymes; Kinetics; Methylation; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Semliki forest virus; Sindbis Virus; Viral Proteins; Virus Replication | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
SCH 79797, a selective PAR1 antagonist, protects against ischemia/reperfusion-induced arrhythmias in the rat hearts.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Male; Myocardial Reperfusion Injury; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1 | 2016 |
Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Topics: Apoptosis; B-Lymphocytes; CD40 Ligand; Cell Proliferation; Cells, Cultured; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-2; Interleukins; Janus Kinase 3; Leukocytes, Mononuclear; Lymphocyte Activation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sirolimus | 2016 |
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.
Topics: Adenine; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line; Dendritic Cells; Female; Immunotherapy; Indoles; Lapatinib; Lymphocytes; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Spleen; Succinates; Sunitinib; Toll-Like Receptor 7 | 2016 |
Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.
Topics: Acetophenones; Animals; Benzopyrans; Chikungunya Fever; Chikungunya virus; Chlorocebus aethiops; Cytopathogenic Effect, Viral; Enzyme Inhibitors; Fibroblasts; Humans; Phorbol Esters; Protein Kinase C; Pyrroles; Quinazolines; Skin; Vero Cells; Virus Replication | 2017 |
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Topics: Animals; Antithrombins; Capillary Permeability; Central Nervous System Agents; Cervical Vertebrae; Disease Models, Animal; Fibrin; Hirudins; Hyperalgesia; Injections, Spinal; Male; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrroles; Quinazolines; Radiculopathy; Rats, Sprague-Dawley; Receptor, PAR-1; Spinal Cord | 2017 |
Effects of protease-activated receptor 1 inhibition on anxiety and fear following status epilepticus.
Topics: Animals; Anxiety; Epilepsy, Temporal Lobe; Fear; Male; Pilocarpine; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Status Epilepticus | 2017 |
Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups.
Topics: Administration, Intranasal; Animals; Animals, Newborn; Antithrombins; Dabigatran; Disease Models, Animal; Extracellular Matrix; Hydrocephalus; Injections, Intraperitoneal; Intracranial Hemorrhages; Maze Learning; Oligopeptides; Pyrroles; Quinazolines; Receptor, PAR-1; Rotarod Performance Test | 2017 |
PAR1‑mediated c‑Jun activation promotes heat stress‑induced early stage apoptosis of human umbilical vein endothelial cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Heat-Shock Response; Human Umbilical Vein Endothelial Cells; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-jun; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Transcription Factor RelA | 2017 |
Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Design; G-Quadruplexes; G1 Phase Cell Cycle Checkpoints; Humans; Ligands; Mice, Inbred BALB C; Molecular Docking Simulation; NM23 Nucleoside Diphosphate Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrroles; Quinazolines; Quinazolinones; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fes; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Tandem Repeat Sequences | 2017 |
FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Models, Molecular; Molecular Docking Simulation; Pyrroles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2 | 2018 |
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2017 |
SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.
Topics: Animals; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; Humans; Lung; Male; Mice; Mice, Inbred C57BL; Neutrophils; Pneumonia, Bacterial; Pyrroles; Quinazolines; Reactive Oxygen Species; Receptor, PAR-1 | 2018 |
PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
Topics: Animals; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Gene Silencing; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oncogene Proteins; Protein Kinase C; Pyrroles; Quinazolines; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2018 |
Protein kinase Cδ (PKCδ) involved in the regulation of pAkt1 (Ser473) on the release of mouse oocytes from diplotene arrest.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Mice; Mice, Inbred Strains; Oocytes; Phosphorylation; Protein Kinase C-delta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Structure-Activity Relationship | 2018 |
The Thrombin Receptor Restricts Subventricular Zone Neural Stem Cell Expansion and Differentiation.
Topics: Animals; Calcium Signaling; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Lateral Ventricles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neural Stem Cells; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin | 2018 |
Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Protein Isoforms; Protein Kinase C-alpha; Proto-Oncogene Proteins c-pim-1; Pyrroles; Quinazolines; Serine | 2018 |
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Topics: Animals; Behavior, Animal; CA1 Region, Hippocampal; Disease Models, Animal; Epilepsy, Temporal Lobe; Lithium; Long-Term Potentiation; Male; Pilocarpine; Pyrroles; Quinazolines; Rats, Wistar; Receptor, PAR-1; Status Epilepticus | 2019 |
Thrombin contributes to the injury development and neurological deficit after acute subdural hemorrhage in rats only in collaboration with additional blood-derived factors.
Topics: Animals; Arginine; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hematoma, Subdural, Acute; Male; Motor Skills; Pipecolic Acids; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines; Random Allocation; Rats, Sprague-Dawley; Severity of Illness Index; Sulfonamides; Thrombin | 2018 |
Thrombin Preconditioning Boosts Biogenesis of Extracellular Vesicles from Mesenchymal Stem Cells and Enriches Their Cargo Contents via Protease-Activated Receptor-Mediated Signaling Pathways.
Topics: Cells, Cultured; Extracellular Vesicles; Humans; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; rab5 GTP-Binding Proteins; Receptor, PAR-1; Signal Transduction; Thrombin; Vesicular Transport Proteins | 2019 |
Sotrastaurin attenuates the stemness of gastric cancer cells by targeting PKCδ.
Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Neoplastic Stem Cells; Protein Kinase C-delta; Pyrroles; Quinazolines; Stomach Neoplasms | 2019 |
Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.
Topics: Animals; Anticoagulants; Disease Models, Animal; Hippocampus; Male; Mice; Pilocarpine; Pyrroles; Quinazolines; Receptor, PAR-1; Status Epilepticus; Thrombin | 2019 |
Effect of miR-196a inhibition on esophageal cancer growth in vitro.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; MicroRNAs; Protein Kinase C; Pyrroles; Quinazolines; Tumor Cells, Cultured | 2020 |
Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines.
Topics: Animals; Animals, Newborn; Astrocytes; Cell Cycle Proteins; Cells, Cultured; Cytokines; Fibrinolysis; Fibrinolytic Agents; Gene Expression; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Plasminogen; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines | 2019 |
BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis.
Topics: Animals; Capillary Permeability; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Mice, Inbred C57BL; Mice, Knockout; Permeability; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptor, PAR-1; Sepsis; Signal Transduction; Thrombin | 2020 |
Morphine induces the differentiation of T helper cells to Th2 effector cells via the PKC-θ-GATA3 pathway.
Topics: Analgesics, Opioid; Animals; Cell Differentiation; GATA3 Transcription Factor; Interferon-gamma; Interleukin-4; Male; Mice, Inbred C57BL; Morphine; Naltrexone; Narcotic Antagonists; Protein Kinase C-theta; Pyrroles; Quinazolines; T-Lymphocytes, Helper-Inducer | 2020 |
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation.
Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic | 2020 |
Thrombin regulates the ability of Schwann cells to support neuritogenesis and to maintain the integrity of the nodes of Ranvier.
Topics: Animals; Calcium; Female; Male; Neurites; Neurogenesis; PC12 Cells; Pyrroles; Quinazolines; Ranvier's Nodes; Rats; Rats, Wistar; Receptor, PAR-1; Schwann Cells; Sciatic Nerve; Thapsigargin; Thrombin | 2020 |
Edoxaban's contribution to key endothelial cell functions.
Topics: Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Pyridines; Pyrroles; Quinazolines; Thiazoles; Wound Healing | 2020 |
Blockade of PAR-1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin-Overexpressing Hypertensive Mice.
Topics: Animals; Collagen Type III; Cytokines; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; HEK293 Cells; Humans; Hypertension; Hypertrophy, Left Ventricular; Inflammation Mediators; Macrophages; Male; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Pyrroles; Quinazolines; Receptor, PAR-1; Renin; Signal Transduction; Transforming Growth Factor beta1; Up-Regulation; Ventricular Function, Left; Ventricular Remodeling | 2020 |
A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance.
Topics: Animals; Anti-Bacterial Agents; Cell Membrane; Drug Resistance, Bacterial; Female; Folic Acid; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Ovariectomy; Proteomics; Pseudomonas aeruginosa; Pyrroles; Quinazolines | 2020 |
Sotrastaurin, a PKC inhibitor, attenuates RANKL-induced bone resorption and attenuates osteochondral pathologies associated with the development of OA.
Topics: Animals; Bone and Bones; Bone Resorption; Cartilage Diseases; Cartilage, Articular; Cattle; Cell Differentiation; Female; Male; Mice; Mice, Inbred C57BL; Osteoarthritis; Osteoclasts; Protein Kinase C; Pyrroles; Quinazolines; RANK Ligand; Signal Transduction | 2020 |
Thrombin alters the synthesis and processing of CYR61/CCN1 in human corneal stromal fibroblasts and myofibroblasts through multiple distinct mechanisms.
Topics: Alternative Splicing; Cell Differentiation; Corneal Stroma; Culture Media, Conditioned; Cysteine-Rich Protein 61; Fibroblast Growth Factor 2; Fibroblasts; Hirudins; Humans; Leupeptins; Myofibroblasts; Primary Cell Culture; Proteolysis; Pyrroles; Quinazolines; Receptors, Proteinase-Activated; RNA, Messenger; Signal Transduction; Stromal Cells; Thrombin; Transforming Growth Factor beta1 | 2020 |
AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model.
Topics: Animals; Female; Lymphocyte Activation; Muscle Weakness; Myasthenia Gravis, Autoimmune, Experimental; Pyrroles; Quinazolines; Rats; Rats, Inbred Lew; T-Lymphocytes, Helper-Inducer | 2020 |
Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Protein Kinase C; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2022 |